Eli Lilly has announced the release of higher doses of its weight loss drug Zepbound in single-dose vials, priced at up to half of its usual monthly list price. This initiative, effective December 11, 2023, aims to increase access for patients without insurance coverage, particularly those on Medicare, as demand for the drug continues to rise.
- Eli Lilly offers higher doses of Zepbound.
- New vials priced lower for uninsured patients.
- Patients self-inject from single-dose vials.
- Compounded versions of Zepbound are declining.
- Medicare beneficiaries lack coverage for Zepbound.
- LillyDirect connects patients with telehealth services.
The launch of higher doses of Zepbound comes as Eli Lilly seeks to address the growing demand for its weight loss medication. The company has introduced 7.5 milligram and 10 milligram vials, which can be purchased directly through its LillyDirect website. This is part of an effort to ensure that patients receive the legitimate medication rather than unregulated compounded alternatives. The lower price points for these vials are designed to benefit those who are willing to self-pay, particularly Medicare beneficiaries who lack coverage for obesity treatments.
Key pricing details include:
- 7.5 milligram vial: $499 (first prescription and refills within 45 days), $599 thereafter.
- 10 milligram vial: $699 (first prescription and refills within 45 days), $799 thereafter.
- Lower doses have also seen a price reduction, with the 2.5 milligram vial now at $349 and the 5 milligram vial at $499.
Patients using the new vials will need to draw the medication using a syringe and needle, differing from the autoinjector pens currently available. Eli Lilly has stated that the vials are easier to manufacture, which will help increase the overall supply of Zepbound. The company aims to ensure that patients do not resort to unapproved alternatives that lack FDA oversight.
While Eli Lilly has not disclosed specific sales figures for the vials, the uptake has reportedly been positive. The launch of these higher doses is expected to further expand the market share of Zepbound among new patients seeking obesity treatment. The company continues to advocate for broader insurance coverage for obesity medications, particularly for Medicare beneficiaries.
The introduction of higher doses of Zepbound at reduced prices reflects Eli Lilly’s commitment to improving access to effective weight loss treatments. By offering these options, the company aims to reach more patients who may otherwise be unable to afford the medication.
